Cobenfy and Abilify are both prescription medicines used for schizophrenia, but they act on different receptors and differ in labeled uses, dosing and side-effect profiles. Cobenfy is the newer of the two and combines xanomeline with trospium chloride. Abilify contains aripiprazole and lists more uses. This page sets the facts side by side so you can take them to your prescriber. It does not name a winner.
Disclosure: Heads up, this page uses affiliate links. When you purchase through them, this site may be paid a commission. You pay no more either way.
Cobenfy vs Abilify at a glance
| Feature | Cobenfy | Abilify |
|---|---|---|
| Company named on the maker’s site | Bristol Myers Squibb (copyright line on cobenfy.com) | Otsuka America Pharmaceutical, Inc. (copyright line on abilify.com) |
| Active ingredient | xanomeline and trospium chloride | aripiprazole |
| Uses the maker lists | Schizophrenia in adults | Schizophrenia (adults and ages 13 to 17); manic or mixed episodes of bipolar I disorder; add-on use for major depressive disorder; irritability associated with autism; Tourette’s Disorder |
| Prescription status | Prescription medicine (cobenfy.com) | Prescription only (Drugs.com) |
| Boxed warning | None (Yale Medicine) | Yes (abilify.com refers to its boxed warning) |
| Reviews on Drugs.com, captured October 29, 2026 | 6.9 out of 10, from 20 ratings | 6.1 out of 10, from 1,229 ratings |
What each medicine is and how it works
Cobenfy
Drugs.com describes Cobenfy as prescribed for schizophrenia. PrescriberPoint names xanomeline as a muscarinic agonist and trospium chloride as a muscarinic antagonist.
Yale Medicine explains why the two are paired. Xanomeline was first tested in the late 1990s to reduce cognitive decline in Alzheimer’s disease, but it caused nausea, vomiting and other gastrointestinal symptoms that people had trouble tolerating. Adding trospium chloride to reduce those effects produced the more tolerable combination that became Cobenfy.
The Cobenfy site lists three capsules: 50 mg/20 mg, 100 mg/20 mg and 125 mg/30 mg. The Cobenfy site says it is taken twice daily on an empty stomach. PubMed Central and PrescriberPoint add that it starts at a lower strength, is taken at least 1 hour before meals or at least 2 hours after a meal, and that capsules should not be opened.
Abilify
Drugs.com lists Abilify’s generic name as aripiprazole, and Abilify’s site sets out its uses. PrescriberPoint’s comparison page describes aripiprazole as an atypical antipsychotic whose effect may be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors, plus antagonist activity at 5-HT2A receptors.
How is Cobenfy different from other antipsychotics?
Yale Medicine notes that antipsychotic drugs that target dopamine directly have been given to people with schizophrenia since the 1950s. It describes Cobenfy as the first of what could be several newer medicines aimed at receptors in the brain other than dopamine. Abilify’s mechanism, as PrescriberPoint describes it, is the partial agonist and antagonist activity listed above, so the two medicines are compared on that difference.
What the research shows for Cobenfy
A review on PubMed Central describes xanomeline as an agonist that prefers the M1 and M4 muscarinic receptors, and the combination as a capsule taken twice daily in 50 mg/20 mg, 100 mg/20 mg and 125 mg/30 mg strengths.
Yale Medicine reports that the FDA approval rested on two identically designed five-week studies with 252 participants, and that the company later presented data from two 52-week extension trials. A Yale Medicine article on Cobenfy quotes one of its psychiatrists calling the new drug promising. The same psychiatrist points out a limit: to be marketed in the U.S., drugs like this only need to show they work better than placebo. Comparing them with existing medicines is left to later studies.
The Cobenfy research centers on schizophrenia. The Abilify uses listed on its site cover more conditions, so the research question for each medicine is different.
Side effects: what each one is known for
Cobenfy side effects
Yale Medicine says the most common side effects participants reported were nausea, indigestion, constipation, vomiting, high blood pressure and reflux (GERD), among others. It notes that the company also reports a risk of liver damage. Cobenfy does not carry an FDA boxed warning, the strongest warning the FDA uses. The Yale psychiatrist calls the absence of a boxed warning good but not a major achievement, given that a relatively small number of people have taken the drug for only five weeks. Longer-term risk, the psychiatrist says, will become clearer over time.
Abilify side effects
Drugs.com’s summary of aripiprazole lists akathisia, sedation, headache, insomnia, agitation, anxiety, nausea and tremors as common side effects. It also says aripiprazole is less likely than some other antipsychotics to cause weight gain. Abilify’s own site says its full prescribing information includes a boxed warning.
What users report
Drugs.com collects side effects from user reviews and states they are “not clinically verified.” On its Abilify page, captured October 29, 2026, the most-reported side effects were weight gain (18.6%), anxiety (9.6%), restlessness (8.8%), insomnia (7.7%), depression (5.6%) and tiredness (4.8%).
If you notice a side effect on either medicine, the Cobenfy site points readers to the FDA’s MedWatch program for reporting, and your prescriber should hear about it first.
Does Cobenfy cause weight gain?
Yale Medicine quotes its psychiatrist on weight. For a person with persistent weight gain on their current antipsychotic that has not responded to changes in diet and exercise, switching to Cobenfy may be worth considering, but with careful follow-up for both weight and any worsening in psychosis symptom control. Weight gain is also the most-reported side effect for Abilify in Drugs.com user reviews. Ask your prescriber how your weight will be tracked on either medicine and how that fits your history.
Can Cobenfy be taken with Abilify?
This comparison cannot settle that. Taking two antipsychotics together is a prescriber decision, and it depends on everything else on your list. Drugs.com’s interaction database lists 760 drugs that interact with aripiprazole and 411 that interact with Cobenfy. Those counts show how many drugs are in the database, not how they would affect you. Bring both names and your full list to your pharmacist and ask for an interaction check before anything changes.
Who should ask a clinician first?
Read each maker’s full prescribing information, or ask your pharmacist for the printed copy, before you decide. Yale Medicine’s psychiatrist advises a very open conversation with your prescriber about potential benefits and side effects, and about how each option compares with what you take now.
Keep a list of every prescription, over-the-counter medicine, vitamin and herbal supplement you use. Show it to your prescriber and pharmacist together, so both can check it against the medicine you are considering.
How much does each one cost?
Check today’s cost with the company or with your pharmacy before you commit. The Cobenfy site has a Savings & Support section and says COBENFY Cares Champions are available 24/7. Yale Medicine advises talking to your insurance provider about whether coverage applies to the drug you are considering, and that step will shape what you pay.
Refund, guarantee and shipping terms
Because both are prescription medicines, ask your pharmacy what it charges, how it handles returns on prescriptions and how long a refill takes.
What buyers say in reviews
Drugs.com’s review pages, captured October 29, 2026, show Cobenfy at 6.9 out of 10 from 20 ratings, with 50% of reviewers reporting a positive effect and 20% a negative one. Abilify is at 6.1 out of 10 from 1,229 ratings, with 49% positive and 34% negative. Cobenfy’s 20 ratings is a small group, and its numbers will move as more people review it.
Who each one may suit
Cobenfy fits a conversation about a schizophrenia medicine with a different mechanism from dopamine-targeting drugs, taken as one capsule twice daily on an empty stomach. Drugs.com lists schizophrenia as the condition Cobenfy is prescribed for. Abilify fits a conversation where the prescribed condition is one of its listed uses: schizophrenia, bipolar I manic or mixed episodes, add-on use for major depressive disorder, irritability associated with autism, or Tourette’s Disorder.
Questions that decide it for you
The research here does not rank one as better than the other. Yale Medicine notes that comparison with existing medicines is left to later studies. These questions decide it for you and your prescriber:
Before you decide
- Which condition is the prescription for? Cobenfy’s site lists schizophrenia in adults; Abilify’s lists several conditions.
- Does a newer mechanism suit your situation, as your prescriber sees it?
- Which other medicines, vitamins and supplements are on your list? Ask your pharmacist to check each one against both medicines.
- Do you have a history of heart, blood pressure, liver, kidney, urinary, stomach or eye problems? Ask your prescriber to go through each maker’s prescribing information with you.
- How will your weight and blood sugar be checked while you take either one?
- Are you pregnant, planning a pregnancy or breastfeeding? Raise this before you start.
- What will each cost with your coverage? Ask your pharmacy for the price before you decide.
- How will you and your prescriber judge whether it is working for you?
By the Clear Health Evidence Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
Leave a Reply